Skip to main content
Equibles

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

Position in SGMT — Sagimet Biosciences Inc.

CIK 884546 SAN FRANCISCO, CA
Back to SGMT Full portfolio

Position in SGMT

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$1,359,490
+$1,281,115 QoQ
Shares Held
175,872
+1072.5% QoQ
Ownership
0.283%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#40
of 122 holders
Holding Since
Sep 2023
9 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in SGMT Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CHARLES SCHWAB INVESTMENT MANAGEMENT INC holds $7,402,603,842 across 299 Biotechnology names. SGMT ranks #210 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 2,041,282 $1,013,966,007
2 REGN
Regeneron Pharmaceuticals, Inc.
 846,306 $527,705,642
3 RVMD
Revolution Medicines, Inc.
 1,917,025 $359,020,441
4 MRNA
Moderna, Inc.
 4,838,884 $338,867,045
5 ALNY
Alnylam Pharmaceuticals, Inc.
 755,377 $227,391,137
6 INCY
Incyte Corp
 1,692,439 $191,854,884
7 RPRX
Royalty Pharma plc
 3,083,528 $172,893,414
8 CYTK
Cytokinetics Inc
 1,565,781 $133,388,883

All Filings in SGMT

Export CSV
9 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,359,490 175,872
2026-03-31 $78,375 15,000
2025-12-31 $88,800 15,000
2025-09-30 $102,900 15,000
2025-06-30 $114,300 15,000
2025-03-31 $48,900 15,000
2024-03-31 $281,129 51,869
2023-12-31 $68,086 12,562
2023-09-30 $110,545 12,562